Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMES 1
jRCT2080223713Phase 3Completed
- Sponsor
- Poxel SA
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Imeglimin 1000 mg twice daily with Placebo (2 arms). Primary endpoint: Change in HbA1c from baseline compared with placebo. Started Nov 2017; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223713.